TTRX · Turn Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · TTRX
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q4 '24 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $109.4K | - | $158.7K | - |
| SG&A | $375.7K | - | $519.7K | - |
| Total Operating Expenses | $385.0K | - | $673.0K | - |
| D&A | - | - | - | - |
| Operating Income | ($1.25M) | - | ($1.91M) | - |
| Interest Expense | - | - | - | - |
| Income Tax | - | - | - | - |
| Net Income | ($971.0K) | - | ($666.4K) | - |
| EPS - Basic | ($0.01) | - | ($0.03) | - |
| EPS - Diluted | ($0.01) | - | ($0.07) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q4 '24 |
|---|---|---|---|---|
| Cash & Equivalents | $11.01M | $4.03M | $498.3K | $498.3K |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | - | - | - | - |
| Current Assets | $11.45M | $5.20M | $3.29M | - |
| Total Assets | $18.64M | $12.16M | $2.05M | - |
| Current Liabilities | $5.13M | $6.00M | $2.31M | - |
| Long-term Debt | $5.94M | - | - | - |
| Total Liabilities | $12.53M | $7.48M | $2.23M | - |
| Stockholders' Equity | $818.7K | $4.69M | ($414.3K) | - |
| Retained Earnings | ($23.36M) | ($22.39M) | ($19.20M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q4 '24 |
|---|---|---|---|---|
| Operating Cash Flow | ($298.1K) | - | - | - |
| Investing Cash Flow | ($12.2K) | - | - | - |
| Financing Cash Flow | $7.79M | - | - | - |
| CapEx | - | - | - | - |
| Free Cash Flow | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q4 '24 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | - | - | - | - |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -5.2% | - | -32.5% | - |
| Return on equity | -118.6% | - | 160.9% | - |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 2.23 | 0.87 | 1.43 | - |
| Quick ratio | 2.23 | 0.87 | 1.43 | - |
| Cash ratio | 2.15 | 0.67 | 0.22 | - |
| Leverage | ||||
| Debt / Equity | 7.25 | - | - | - |
| Debt / Assets | 0.32 | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | - | - | - |
| Equity multiplier | 22.77 | 2.60 | -4.95 | - |
| Liabilities / Assets | 0.67 | 0.61 | 1.09 | - |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | 105.4x | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - |
| Net income growth (YoY) | - | - | - | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Turn Therapeutics Inc. against the 5 most active filers in the same SIC group.